Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

HALO stock hub

Halozyme Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HALOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

7.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

HALO

In the news

Latest news · HALO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E7.9

P25 12.3P50 18.4P75 33.1

Trailing P/E25

P25 14.9P50 23.2P75 38.5

ROE153.6

P25 -105.6P50 -46.5P75 -3.1

ROIC32.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HALO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

265

Groups with data

Currency

USD

Showing 265 of 265 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001159036
Company name	Halozyme Therapeutics, Inc.
Country	United States
Country code	US
Cusip	40637H109
Employees	423
Employees Change	73%
Employees Change Percent	20.86
Enterprise value	$9.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US40637H1095
Last refreshed	2026-05-10
Market cap	$7.6B
Market cap category	Mid-Cap
Price	$64.12
Price currency	USD
Rev Per Employee	3,301,680.85x
Sector	Healthcare
Sic	2836
Symbol	HALO
Website	https://halozyme.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.17%
EV Earnings	30.39x
EV Sales Forward	5.37x
EV/EBIT	11.8x
EV/EBITDA	10.73x
EV/FCF	14.94x
EV/Sales	6.9x
FCF yield	8.49%
Forward P/E	7.93x
P/B ratio	154.71x
P/E ratio	25.05x
P/S ratio	5.44x
PE Ratio10 Y	30.58x
PE Ratio3 Y	18.49x
PE Ratio5 Y	20.41x
PS Forward	4.23x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	58.45%
EBITDA Margin	64.29%
FCF margin	46.15%
Gross margin	77.78%
Gross Profit	$1.1B
Gross Profit Growth	39.84%
Gross Profit Growth Q	44.83%
Gross Profit Growth3 Y	33.73%
Gross Profit Growth5 Y	41.73%
Net Income	$316.9M
Net Income Growth	-28.64%
Net Income Growth Years	0%
Net Income Growth3 Y	16.17%
Net Income Growth5 Y	19.68%
Pretax Margin	33.43%
Profit Margin	22.69%
Profit Per Employee	$749,147
Profitable Years	6
ROA	22.24
Roa5y	16.99
ROCE	34.76
ROE	153.6
Roe5y	183.2
ROIC	32.36
Roic5y	44.43

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	21.04%
Cagr15y	16.68%
Cagr1y	-8.59%
Cagr20y	16.99%
Cagr3y	27.41%
Cagr5y	6.15%
EPS Growth	-25.36
EPS Growth Years	0
EPS Growth3 Y	21.14
EPS Growth5 Y	22.98
FCF Growth	37.62%
FCF Growth Q	24.05%
FCF Growth3 Y	39.92%
FCF Growth5 Y	64.85%
OCF Growth	36.01%
OCF Growth Q	22.73%
OCF Growth3 Y	39.48%
OCF Growth5 Y	63.68%
Revenue Growth	37.55x
Revenue Growth Q	51.6x
Revenue Growth Quarters	16x
Revenue Growth Years	7x
Revenue Growth3 Y	28.38x
Revenue Growth5 Y	39.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.61
Assets	$2.5B
Cash	$142.8M
Current Assets	$825.2M
Current Liabilities	$177.1M
Debt	$2.2B
Debt EBITDA	$2.4
Debt Equity	$44.6
Debt FCF	$3.38
Equity	$48.8M
Interest Coverage	45.03
Liabilities	$2.5B
Long Term Assets	$1.7B
Long Term Liabilities	$2.3B
Net Cash	$-2B
Net Cash By Market Cap	$-26.78
Net Debt EBITDA	$2.27
Net Debt Equity	$41.68
Net Debt FCF	$3.16
Tangible Book Value	$-1.5B
Tangible Book Value Per Share	$-12.85
WACC	7.21

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.66
Inventory Turnover	1.95
Net Working Capital	$516.6M
Quick ratio	3.3
Working Capital	$648.1M
Working Capital Turnover	$1.75

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	4.27%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	574.95%
1Y total return	-8.58%
200-day SMA	68.67
3Y total return	106.84%
50-day SMA	65.63
50-day SMA vs 200-day SMA	50under200
5Y total return	34.79%
All Time High	82.22
All Time High Change	-22.01%
All Time High Date	2026-02-09
All Time Low	1.41
All Time Low Change	4,447.52%
All Time Low Date	2004-08-17
ATR	1.97
Beta	0.88
Beta1y	-0.17
Beta2y	0.46
Ch YTD	-4.73
High	65.78
High52	82.22
High52 Date	2026-02-09
High52ch	-22.01%
Low	64
Low52	47.5
Low52 Date	2025-05-14
Low52ch	34.99%
Ma50ch	-2.3%
Premarket Change Percent	1.72
Premarket Price	$66.31
Premarket Volume	843
Price vs 200-day SMA	-6.63%
RSI	43.84
RSI Monthly	54.09
RSI Weekly	45.43
Sharpe ratio	-0.13x
Sortino ratio	-0.03
Total Return	4.27%
Tr YTD	-4.73
Tr15y	911.36%
Tr1m	0.82%
Tr1w	0.25%
Tr3m	-21.06%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	6
Analyst Price Target Top	$75.5
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.51
Earnings EPS Estimate Growth	36.04
Earnings Revenue Estimate	358,788,720x
Earnings Revenue Estimate Growth	35.46x
Operating Income	$816.3M
Operating Income Growth	48.02
Operating Income Growth Q	44.95
Operating Income Growth3 Y	41.29
Operating Income Growth5 Y	41.43
Operating margin	58.45
Price target	$78.64
Price Target Change	$22.65
Price Target Change Top	$17.75

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	117,160,177%
Float Percent	98.89%
Net Borrowing	624,574,000
Shares Insiders	1.02%
Shares Institutions	105.49%
Shares Out	118,474,300
Shares Qo Q	-3.81%
Shares Yo Y	-4.27%
Short Float	12.17%
Short Ratio	9.92
Short Shares	12.03

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$593M
Average Volume	1,344,003.7x
Bv Per Share	0.41
CAPEX	$-7M
Ch10y	574.9
Ch15y	911.4
Ch1m	0.82
Ch1w	0.25
Ch1y	-8.58
Ch20y	2,206.5
Ch3m	-21.06
Ch3y	106.8
Ch5y	34.79
Ch6m	-6.04
Change	-1.64%
Change From Open	-2.02
Close	65.19
Days Gap	0.38
Depreciation Amortization	81,551,000
Dollar Volume	105,824,225.1
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$816.3M
EBITDA	$897.8M
EPS	$2.56
F Score	6
FCF	$644.6M
FCF EV Yield	6.69x
FCF Per Share	$5.44
Financing CF	-85,174,000
Fiscal Year End	December
Founded	1,998
Goodwill	580,360,000
Graham Number	4.88589
Graham Upside	-92.38
Income Tax	$150M
Investing CF	-545,813,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-17
Last Report Date	2025-12-31
Last Split Date	2003-12-10
Last Split Type	Forward
Last10k Filing Date	2026-02-17
Lynch Fair Value	$50.37
Lynch Upside	-21.44
Ma150	68.25
Ma150ch	-6.05%
Ma20	66.09
Ma20ch	-2.98%
Net CF	20,571,000
Next Earnings Date	2026-05-11
Open	65.44
Optionable	Yes
P FCF Ratio	11.79
P OCF Ratio	11.66
Position In Range	6.74
Post Close	64.12
Postmarket Change Percent	0.19
Postmarket Price	$64.24
Ppne	82,137,000
Pre Close	65.19
Price Date	2026-05-08
Price EBITDA	$8.46
Relative Volume	1.23x
Revenue	1,396,611,000x
SBC By Revenue	3.69x
Share Based Comp	51,565,000
Tax By Revenue	10.74x
Tax Rate	32.13%
Tr20y	2,206.48%
Tr6m	-6.04%
Us State	California
Volume	1,650,409
Z Score	3.78

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does HALO pay a dividend?

Capital-return profile for this ticker.

Performance

HALO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HALO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+105.5%

Float: +98.9% of shares outstanding

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

HALO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.8

Neutral momentum band

Price vs 200-day MA

-6.6%

50/200-day relationship not available

Beta (5Y)

0.88

Moves roughly with the market

Sharpe ratio

-0.13

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HALO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current HALO stock rating?

Halozyme Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HALO analysis?

The full report lives at /stocks/HALO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for HALO?

The latest report frames HALO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the HALO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.